Inhibition of matrix metalloproteinases attenuates anti-Thy 1.1 Nephritis

Journal of the American Society of Nephrology

Volumn 9, Issue 3, 1998, Pages 397-407

  Steinmann Niggli, Karin ^a   Ziswiler, Ruth ^a   Küng, Marc ^a   Marti, Hans Peter ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BB 1101; GELATINASE A; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; GLOMERULONEPHRITIS; HISTOPATHOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031890320     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Johnson RJ, Lombardi D, Eng E, Gordon K, Alpers CE, Pritzl P, Floege J, Young B, Pippin J, Couser WG, Gabbiani G: Modulation of experimental mesangial proliferative nephritis by Interferon-γ. Kidney Int 47: 62-69, 1995
2. Agaki Y, Isaka Y, Arai M, Kaneko T, Takenaka M, Moriyama T, Kaneda Y, Ando A, Orita Y, Kamada T, Ueda N, Imai E: Inhibition of TGF-β1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 50: 148-155, 1996
3. Birkedal-Hansen H: Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 7: 728-735, 1995
4. Woessner JF: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5: 2145-2154, 1991
5. Conway JG, Wakefield JA, Brown RH, Marron BE, Sekut L, Stimpson SA, McElroy A, Menius JA, Jeffreys JJ, Clark RL, McGeehan GM, Connolly KM: Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J Exp Med 182: 449-457, 1995
6. Gijbels K, Galdary RE, Steinmann L: Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 94: 2177-2182, 1994
7. Dean DD, Martel-Pelletier J, Howell DS, Woessner JF: Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 84: 678-685, 1989
8. Vincenti MP, Clark IM, Brinckerhoff CE: Using inhibitors of metalloproteinases to treat arthritis: Easier said than done? Arthritis Rheum 37: 1115-1126, 1994
9. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64: 327-336, 1991
10. Matrisian LM: Metalloproteinases and their inhibitors in matrix-remodeling. Trends Genet 6: 121-125, 1990
11. Marti HP, McNeil L, Thomas G, Davies M, Lovett DH: Molecular characterization of a low molecular-mass matrix metalloproteinase secreted by glomerular mesangial cells as Pump-1. Biochem J 285: 899-905, 1992
12. Miyazaki M, Koji T, Furusu A, Abe K, Ozono Y, Hara K, Harada T, Nakane PK, Suzuki D, Yagame M, Endoh M, Nomoto Y, Sakai H: Expression of stromelysin (str) mRNA and TIMP-1 mRNA in human diseased kidney [Abstract]. J Am Soc Nephrol 6: 902, 1995
13. Marti HP, Lee L, Kashgarian M, Lovett DH: Transforming growth factor-β1 stimulates glomerular mesangial cell synthesis of the 72-kd type IV collagenase. Am J Pathol 144: 82-94, 1994
14. Lovett DH, Johnson RJ, Marti HP, Martin J, Davies M, Couser WG: Structural characterization of the mesangial cell type IV collagenase and enhanced expression in a model of immune complex-mediated glomerulonephritis. Am J Pathol 141: 85-98, 1992
15. Floege J, Johnson RJ, Gordon K, Iida H, Pritzl P, Yoshimura A, Campbell C, Alpers CE, Couser WG: Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int 40: 477-488, 1991
16. Nixon JS, Bottomley KM, Broadhurst MJ, Brown PA, Johnson WH, Lawton G, Marley J, Sedgwick AD, Wilkinson SE: Potent collagenase inhibitors prevent interleukin-1-induced cartilage destruction in vitro. Int J Tissue React 13: 237-241, 1991
17. McGeehan GM, Becherer JD, Bast RC Jr, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S, McElroy AB, Nichols J, Pryzwanski KM, Schoenen F, Sekut S, Truesdale A, Verghese M, Warner J, Ways JP: Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature (Lond) 370: 558-561, 1994
18. Mason DW, Williams AF: The kinetics of antibody binding to membrane antigens in solution and at the cell surface. Biochem J 187: 1-20, 1980
19. Falkenberg FW, Hengelage T, Krane M, Bartels I, Albrecht A, Holtmeier N, Wüthrich M: A simple and inexpensive high-density dialysis tubing cell culture system for the in vitro production of monoclonal antibodies in high concentration. J Immunol Methods 165: 193-206, 1993
20. Lindmark R, Thorén-Tolling K, Sjöquist J: Binding of immunoglobulins to protein A and immunoglobulin levels in mammalian sera. J Immunol Methods 62: 1-13, 1983
21. Matyszak MK, Perry VH: Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitors of matrix metalloproteinases. J Neuroimmunol 69: 141-149, 1996
22. Steinmann-Niggli K, Lukes M, Marti HP: Rat mesangial cells and matrix metalloproteinase inhibitor: Inhibition of 72 kD type IV collagenase (MMP-2) and of cell proliferation. J Am Soc Nephrol 8: 395-405, 1997
23. Sier CFM, Kubben FJGM, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, van Krieken JHJM, Lamers CBHW, Verspaget HW: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 74: 413-417, 1996
24. Gibaldi M, Perrier D: Appendix D. In: Pharmacokinetics, edited by Swarbrick J, Chapel Hill, Marcel Dekker Inc., 1982, pp 445-449
25. Marks LS, Treiger B, Dorey FJ, Fu YS, de Kernion JB: Morphometry of the prostate. I. Distribution of tissue components in hyperplastic glands. Urology 44: 486-492, 1994
26. Sato T, van Dixhoorn MG, Schroeijers WE, Huizinga TW, Reutelingsperger CP, van Es LA, Daha MR: Apoptosis of cultured rat glomerular mesangial cells induced by IgG2a monoclonal anti-Thy-1 antibodies. Kidney Int 49: 403-412, 1996
27. Narita I, Border WA, Ketteler M, Noble NA: Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis. Lab Invest 72: 17-24, 1995
28. Floege J, Eng E, Young BA, Couser WG, Johnson RJ: Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. Kidney Int 43: 369-380, 1993
29. Studer H, Gerber H, Zbaeren J, Peter HJ: Histomorphological and immunohistochemical evidence that human nodular goiters grow by episodic replication of multiple clusters of thyroid follicular cells. J Clin Endocrinol Metab 75: 1151-1158, 1992
30. Roy-Chaudhury P, Wu B, McDonald S, Haites NE, Simpson JG, Power DA: Phenotypic analysis of the glomerular and periglomerular mononuclear cell infiltrates in the Thy 1.1 model of glomerulonephritis. Lab Invest 72: 524-531, 1995
31. Floege J, Eng E, Lindner V, Alpers CE, Young BA, Reidy A, Johnson RJ: Rat glomerular mesangial cells synthesize basic fibroblast growth factor: Release, upregulated synthesis, and mitogenicity in mesangial proliferative glomerulonephritis. J Clin Invest 90: 2362-2369, 1992
32. Kirschfink M, Fritze H, Roelcke D: Complement activation by cold agglutinins. Vox Sang 63: 220-226, 1992
33. Süsal C, Kirschfink M, Kröpelin M, Daniel V, Opelz G: Complement activation by recombinant HIV-1 glycoprotein gp120. J Immunol 152: 6028-6034, 1994
34. Marti HP, McNeil L, Davies M, Martin J, Lovett DH: Homology cloning of rat 72 kDa type IV collagenase: Cytokine and second messenger inducibility in glomerular mesangial cells. Biochem J 291: 441-446, 1993
35. Floege J, Eng E, Young B, Johnson RJ: Factors involved in the regulation of mesangial cell proliferation in vivo and in vitro. Kidney Int 39[Suppl]: S47-S54, 1993
36. Hogg RJ, Waldo B: Advances in treatment: Immunoglobulin A nephropathy. Semin Nephrol 16: 511-516, 1996
37. Black RM: IgA nephropathy. In: Clinical Problems in Nephrology, 1st Ed., edited by Rose BD, Black RM, Boston, Little, Brown, and Co., 1996, pp 317-323
38. Border WA, Okuda S, Languito LR, Sporn MB, Ruoslahti E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature (Lond) 346: 371-374, 1990
39. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E: Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature (Lond) 360: 361-364, 1992
40. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, Border WA: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 2: 418-423, 1996
41. Johnson RJ, Raines EW, Floege J, Yoshimura A, Pritzl P, Alpers C, Ross R: Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 175: 1413-1416, 1992
42. Stahl RA, Thaiss F, Oberle G, Brecht HM, Schoeppe W, Wenzel U, Helmchen UM: The platelet activating factor receptor antagonist WEB 2170 improves glomerular hemodynamics and morphology in a proliferative model of mesangial cell injury. J Am Soc Nephrol 2: 37-44, 1991
43. Poelstra K, Brouwer E, Baller JF, Hardonk MJ, Bakker WW: Attenuation of anti-Thy1 glomerulonephritis in the rat by anti-inflammatory platelet-inhibiting agents. Am J Pathol 142: 441-450, 1993
44. Turck J, Pollock AS, Lee LK, Marti HP, Lovett DH: Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation. J Biol Chem 271: 15074-15083, 1996
45. Turck J, Pollock AS, Lovett DH: Gelatinase A is a glomerular mesangial cell growth and differentiation factor. Kidney Int 51: 1397-1400, 1997
46. Johnson RJ, Iida H, Alpers CE, Majeski MW, Schwartz SM, Pritzl P, Gordon K, Gown AM: Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis: Alpha-smooth muscle actin is a marker of mesangial cell proliferation. J Clin Invest 87: 847-858, 1991
47. Kawamata H, Kawai K, Kameyama S, Johnson MD, Stetler-Stevenson WG, Oyasu R: Over-expression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. Int J Cancer 63: 680-687, 1995